Pfizer jettisons IVD line
This article was originally published in The Gray Sheet
Executive Summary
European private equity firm Triton and PPM Ventures, an arm of Prudential, acquire in vitro allergy and autoimmune diagnostic testing business from Pfizer for $575 mil. Divestiture of the Sweden-based business had been projected since July, one year after the drug giant bought Pharmacia (1"The Gray Sheet" July 7, 2003, p. 8)...
You may also be interested in...
Pharmacia Device/Diagnostics Unit Ripe For Picking, Pfizer Says
Pfizer's July 1 announcement that it will explore strategic options for divesting Pharmacia's device and diagnostics division confirms the company's intentions to shed non-core assets
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.